CD55, also known as Decay-accelerating factor (DAF) is an inhibitor of the complement system, and is broadly expressed in malignant tumours. In cancer, CD55 has been implicated in tumorigenesis, neoangiogenesis, and metastasis. CD55 may decrease complement mediated tumor cell lysis, inhibit tumor apoptosis, and promote invasive cancer cell motility. These roles in cancer may involve binding to the seven-span transmembrane receptor CD97. In neuroblastoma cells, CD55 contributes to growth of colonies and to invasion of cells, but not to stemness. In neuroblastoma cells, CD55 is upregulated in a small population of cells that are HIF-2α positive. This CD55 positive subpopulation is highly invasive and has low adhesion to fibronectin and collagen. In addition, CD55 expression correlates with poor prognosis in neuroblastoma patients.
References
Cimmino F et al. (2016) Oncogenesis 5:e212.Mikesch JH et al.(2006) Cell Oncol. 28(5-6):223.
Western blot analysis of native lysates: human A549 (lane 1), MDA-MB-231 (lane 2), and A431 (lane 3) cell lines, and lung tissue (lane 4). The blot was probed with mouse monoclonal anti-CD55 (CM0021) at 1:500.
Immunocytochemical labeling of CD55 in paraformaldehyde fixed human MDA-MB-231 breast cancer cells. The cells were labeled with mouse monoclonal anti-CD55 (CM0021). The antibody was detected using goat anti-mouse DyLight® 594.
*For more information, see UniProt Accession P08174
The products are are safely shipped at ambient temperature for both domestic and international shipments. Each product is guaranteed to match the specifications as indicated on the corresponding technical data sheet. Please store at -20C upon arrival for long term storage.
*All molecular weights (MW) are confirmed by comparison to Bio-Rad Rainbow Markers and to western blotmobilities of known proteins with similar MW.
This kit contains:
